AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15014006 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous formalin‐fixed tumor vaccine (AFTV)
Number of subjects: 41
Study 15014006 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant control
Number of subjects: 41
Study 12409970 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75 mg daily)
Number of subjects: 18790
Study 12409970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18790
Study 12409970 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75 mg daily) in patients with serum creatinine > 1.3 mg/dl
Number of subjects: 18790
Study 12409970 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75 mg daily) in subgroups at higher global baseline risk or higher initial blood pressures
Number of subjects: 18790
Study 9613307 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g EMLA (group E)
Number of subjects: 54
Study 9613307 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml 1% mepivacaine (group M)
Number of subjects: 54
Study 9613307 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml 0.25% bupivacaine (group B)
Number of subjects: 54
Study 7584486 — intervention group
Group type: EXPERIMENTAL
Intervention: XZ‐CD5 0.1 mg kg‐1 day‐1 intravenously with high‐dose methyl‐prednisolone for 10, 14 or 17 doses
Number of subjects: 11
Study 7584486 — intervention group
Group type: EXPERIMENTAL
Intervention: XZ‐CD5 and cyclosporine (CSA) for 17 doses
Number of subjects: 11
Study 2782570 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia in anaesthetic room
Number of subjects: 100
Study 2782570 — intervention group
Group type: COMPARATOR
Intervention: Anaesthesia in operating theatre
Number of subjects: 100
Study 4473 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 16
Study 4473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31437302 — intervention group
Group type: EXPERIMENTAL
Intervention: DNL104 (a centrally penetrant RIPK1 inhibitor)
Number of subjects: 68
Study 31437302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 31254640 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg/day titrated to 40 mg/day
Number of subjects: 70
Study 31254640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 31254640 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 70
Study 28585834 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavan-3-ol-enriched dark chocolate
Number of subjects: 42
Study 28585834 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dark chocolate
Number of subjects: 42
Study 28585834 — intervention group
Group type: COMPARATOR
Intervention: White chocolate
Number of subjects: 42
Study 26576593 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib plus bevacizumab, 7.5 mg/kg i.v. every 3 weeks
Number of subjects: 12
Study 26576593 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg (standard) or 800 mg (for patients with exon 9 KIT mutations)
Number of subjects: 12
Study 23662289 — intervention group
Group type: EXPERIMENTAL
Intervention: CR oxycodone/CR naloxone (10 mg/5 mg every 12 h, titrated to 20 mg/10 mg, 30 mg/15 mg, or 40 mg/20 mg)
Number of subjects: 83
Study 23662289 — intervention group
Group type: EXPERIMENTAL
Intervention: CR oxycodone/CR naloxone
Number of subjects: 83
Study 23662289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 22238849 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback and nonnegative social feedback from a confederate
Number of subjects: 25
Study 22238849 — intervention group
Group type: COMPARATOR
Intervention: Control group (watched video of another person's speech)
Number of subjects: 25
Study 19635893 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of WHO MDT (dapsone, clofazimine, rifampin)
Number of subjects: 189
Study 19635893 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of WHO MDT
Number of subjects: 189
Study 19635893 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 month of daily rifampin and daily ofloxacin
Number of subjects: 189
Study 19635893 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of WHO MDT plus an initial 1 month of daily rifampin and daily ofloxacin
Number of subjects: 189
Study 16413239 — intervention group
Group type: EXPERIMENTAL
Intervention: 500% recombinant human antithrombin
Number of subjects: 30
Study 16413239 — intervention group
Group type: EXPERIMENTAL
Intervention: 200% recombinant human antithrombin
Number of subjects: 30
Study 16413239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15570116 — intervention group
Group type: EXPERIMENTAL
Intervention: L3‐L4 disc herniation (study group)
Number of subjects: 37
Study 15570116 — intervention group
Group type: COMPARATOR
Intervention: L4‐L5 and L5‐S1 herniation (control group)
Number of subjects: 37
Study 11157686 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 1480
Study 11157686 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1480
Study 9364542 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2) as a single agent
Number of subjects: 0
Study 9364542 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (20% to 21%) after failing cisplatin-based chemotherapy
Number of subjects: 0
Study 9364542 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2) and Cisplatin (75 mg/m2)
Number of subjects: 0
Study 9364542 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (90 mg/m2 without G-CSF support) and Carboplatin
Number of subjects: 0
Study 9364542 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2 with G-CSF support) and Carboplatin
Number of subjects: 0
Study 8496758 — intervention group
Group type: COMPARATOR
Intervention: Standard mixture containing 1.25 mmol calcium and 1.5 mmol phosphorus per deciliter (group STAND: n = 12)
Number of subjects: 24
Study 8496758 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 mmol calcium and 2.0 mmol phosphorus per deciliter (group HIGH: n = 12)
Number of subjects: 24
Study 3629488 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron preparations combined with vitamins B12 and B6, copper sulfate, and the combination of iron with the vitamin B group and copper sulfate.
Number of subjects: 250
Study 3629488 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron preparations administered for injection.
Number of subjects: 250
Study 3629488 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent therapy after hemoglobin normalization.
Number of subjects: 250
Study 3629488 — intervention group
Group type: COMPARATOR
Intervention: Iron preparations combined with other preparations.
Number of subjects: 250
Study 30285151 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively Smoke Free‐Mobile (PSF‐M)
Number of subjects: 100
Study 30285151 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 28693841 — intervention group
Group type: EXPERIMENTAL
Intervention: Tattooing (T group)
Number of subjects: 80
Study 28693841 — intervention group
Group type: COMPARATOR
Intervention: No tattooing (C group)
Number of subjects: 80
Study 27213646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 106
Study 27213646 — intervention group
Group type: COMPARATOR
Intervention: Menopause Education Control (MEC)
Number of subjects: 106
Study 23844613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite 200 mcg daily for 6 months
Number of subjects: 61
Study 23844613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 20964568 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitric oxide 3% plus cryotherapy
Number of subjects: 63
Study 20964568 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy plus placebo
Number of subjects: 63
Study 21186534 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV, 10 mg/d)
Number of subjects: 80
Study 21186534 — intervention group
Group type: COMPARATOR
Intervention: Other nucleoside analogues (for 19 patients who switched)
Number of subjects: 80
Study 19007655 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 0
Study 16798759 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing for 1 month
Number of subjects: 92
Study 16798759 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdrive pacing for 3 months
Number of subjects: 92
Study 16798759 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing for 4 months
Number of subjects: 92
Study 11982739 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IFN-alpha induction therapy (6 MIU daily for 4 weeks and 3 MIU 3/7 days for 22 weeks)
Number of subjects: 254
Study 11982739 — intervention group
Group type: COMPARATOR
Intervention: Conventional IFN-alpha therapy (3 MIU 3/7 days for 26 weeks)
Number of subjects: 254
Study 11982739 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with thyroid dysfunction
Number of subjects: 254
Study 11982739 — intervention group
Group type: COMPARATOR
Intervention: Patients without thyroid dysfunction
Number of subjects: 254
Study 10432413 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 14
Study 10432413 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14
Study 7607717 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine
Number of subjects: 15
Study 7607717 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 15
Study 7607717 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 2215105 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 40
Study 2215105 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (5 mg/kg)
Number of subjects: 40
Study 576328 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphasic screening group (SG)
Number of subjects: 112
Study 576328 — intervention group
Group type: COMPARATOR
Intervention: Chart abstract group (AG)
Number of subjects: 112
Study 576328 — intervention group
Group type: COMPARATOR
Intervention: Chart review group (RG)
Number of subjects: 112
Study 31277154 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 40
Study 31277154 — intervention group
Group type: COMPARATOR
Intervention: Tongue scraper
Number of subjects: 40
Study 28721881 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (PORT) at 57.6 Gy or 63 Gy for lower-risk group; 63 Gy or 68.4 Gy for higher-risk group, all at 1.8 Gy per fraction.
Number of subjects: 264
Study 26297187 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of plasma products
Number of subjects: 14
Study 26297187 — intervention group
Group type: COMPARATOR
Intervention: Infusion of albumin solution
Number of subjects: 14
Study 23176678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated milk (5 ppm fluoride, 200 ml daily)
Number of subjects: 64
Study 23176678 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoridated milk (200 ml daily)
Number of subjects: 64
Study 23176678 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 21777153 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-second rest interval group (n = 8)
Number of subjects: 16
Study 21777153 — intervention group
Group type: COMPARATOR
Intervention: 1-minute rest interval group (n = 8)
Number of subjects: 16
Study 21777153 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (10s and 1min)
Number of subjects: 16
Study 19324954 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAd)
Number of subjects: 59
Study 19324954 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 59
Study 16676826 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon catheter dilation of sinus ostia
Number of subjects: 10
Study 15451898 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection of the pylorus (200 units)
Number of subjects: 8
Study 11165992 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment and prevention options for NSAID-associated ulcers
Number of subjects: 0
Study 10890384 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL2) 5 million units/m2 once daily by constant intravenous infusion (CI) 5 days/week for 2 weeks
Number of subjects: 22
Study 10890384 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-2 (IL2) 5 million units/m2 once daily by subcutaneous bolus (SB) injection 5 days/week for 2 weeks
Number of subjects: 22
Study 8792180 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms/24 h estradiol‐17‐beta
Number of subjects: 15
Study 8792180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1636702 — intervention group
Group type: EXPERIMENTAL
Intervention: +T3 group
Number of subjects: 16
Study 1636702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure
Number of subjects: 16
Study 1636702 — intervention group
Group type: COMPARATOR
Intervention: ‐T3 group
Number of subjects: 16
Study 6733832 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated condition
Number of subjects: 10
Study 6733832 — intervention group
Group type: COMPARATOR
Intervention: Standing condition
Number of subjects: 10
Study 6733832 — intervention group
Group type: COMPARATOR
Intervention: One-leg condition
Number of subjects: 10
Study 6733832 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-legs condition
Number of subjects: 10
Study 6733832 — intervention group
Group type: COMPARATOR
Intervention: Cued stepping
Number of subjects: 10
Study 6733832 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced stepping
Number of subjects: 10
Study 6733832 — intervention group
Group type: EXPERIMENTAL
Intervention: Training sessions (10 sessions)
Number of subjects: 10
Study 30001745 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™) at 26 mg/kg (1×)
Number of subjects: 32
Study 30001745 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™) at 78 mg/kg (3×)
Number of subjects: 32
Study 30001745 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™) at 130 mg/kg (5×)
Number of subjects: 32
Study 30001745 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham-dosed)
Number of subjects: 32
Study 27596059 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h plasma glucose >8.6mmol/l (155mg/dl)
Number of subjects: 1970
Study 27596059 — intervention group
Group type: COMPARATOR
Intervention: 1-h plasma glucose ≤8.6mmol/l (155mg/dl) and 2-h-PG <7.8mmol/l (140mg/dl)
Number of subjects: 1970
Study 24275482 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate cautery
Number of subjects: 65
Study 24275482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 22379112 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment of end-diastolic interventricular septal wall thickness (IVSTd)
Number of subjects: 205
Study 22379112 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of myocardial mass and left ventricular function
Number of subjects: 205
Study 22379112 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of regional myocardial function
Number of subjects: 205
Study 22379112 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of neurological function
Number of subjects: 205
Study 19380175 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant treatment (gemcitabine for a maximum of 6 cycles plus cetuximab until progression)
Number of subjects: 100
Study 19380175 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment (gemcitabine for a maximum of 6 cycles followed by cetuximab)
Number of subjects: 100
Study 19380175 — intervention group
Group type: COMPARATOR
Intervention: Concomitant treatment (CALC1-E)
Number of subjects: 100
Study 17601037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological cardioversion (PC) with nibentan
Number of subjects: 97
Study 17601037 — intervention group
Group type: COMPARATOR
Intervention: Electrical cardioversion (EC)
Number of subjects: 97
Study 16261973 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional, computer-based, virtual training simulator
Number of subjects: 167
Study 16261973 — intervention group
Group type: COMPARATOR
Intervention: Standard emergency medical technician training
Number of subjects: 167
Study 12355477 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34-selected cells
Number of subjects: 33
Study 12355477 — intervention group
Group type: COMPARATOR
Intervention: Unmanipulated cells
Number of subjects: 33
Study 9870121 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening questionnaires placed in charts with concerns highlighted for referrals (experimental group of 209 subjects)
Number of subjects: 619
Study 9870121 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and treatment (experimental group)
Number of subjects: 619
Study 9870121 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control groups)
Number of subjects: 619
Study 7731498 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (2 micrograms/kg i.v.)
Number of subjects: 6
Study 7731498 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (2 micrograms/kg i.v.) + GHRH (2 micrograms/kg i.v.)
Number of subjects: 6
Study 7731498 — intervention group
Group type: COMPARATOR
Intervention: GHRH (2 micrograms/kg i.v.)
Number of subjects: 6
Study 2233598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg/day)
Number of subjects: 34
Study 2233598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg/day) + Acebutolol (200 mg/day)
Number of subjects: 34
Study 2233598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg/day) + Hydrochlorothiazide (25 mg/day)
Number of subjects: 34
Study 30826468 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative content (criticism)
Number of subjects: 152
Study 30826468 — intervention group
Group type: EXPERIMENTAL
Intervention: Hostile tone of feedback
Number of subjects: 152
Study 30826468 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative tone with negative content
Number of subjects: 152
Study 30826468 — intervention group
Group type: COMPARATOR
Intervention: Neutral content
Number of subjects: 152
Study 30826468 — intervention group
Group type: COMPARATOR
Intervention: Neutral tone
Number of subjects: 152
Study 29215160 — intervention group
Group type: EXPERIMENTAL
Intervention: STAN2007
Number of subjects: 151
Study 29215160 — intervention group
Group type: COMPARATOR
Intervention: FIGO2015
Number of subjects: 151
Study 29215160 — intervention group
Group type: COMPARATOR
Intervention: SSOG2017
Number of subjects: 151
Study 29215160 — intervention group
Group type: COMPARATOR
Intervention: Old and new CTG classification systems
Number of subjects: 151
Study 26945347 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial status indicators (depression, anxiety, social support) assessed at enrollment
Number of subjects: 0
Study 26945347 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms
Number of subjects: 0
Study 26945347 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anxiety levels
Number of subjects: 0
Study 26945347 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline social support
Number of subjects: 0
Study 26945347 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of stigmatizing experiences
Number of subjects: 0
Study 26945347 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial determinants
Number of subjects: 0
Study 26945347 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of psychosocial interventions to reduce depression and anxiety
Number of subjects: 0
Study 24956095 — intervention group
Group type: EXPERIMENTAL
Intervention: Test implants with platform switching
Number of subjects: 53
Study 24956095 — intervention group
Group type: COMPARATOR
Intervention: Similar nonplatform-switched controls
Number of subjects: 53
Study 22067112 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced carbohydrate diet (SPEC: 42% energy from CHO)
Number of subjects: 26
Study 22067112 — intervention group
Group type: COMPARATOR
Intervention: Standard carbohydrate diet (STAN: 55% energy from CHO)
Number of subjects: 26
Study 20634594 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 904
Study 20634594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 904
Study 18567650 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear Torsional combined with Ultrasound power (Linear Tor+US group, n = 66)
Number of subjects: 198
Study 18567650 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Fixed Torsional group (Fixed Tor group, n = 65)
Number of subjects: 198
Study 18567650 — intervention group
Group type: COMPARATOR
Intervention: Conventional Ultrasound burst group (US group, n = 67)
Number of subjects: 198
Study 16037143 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (0.1 mg/kg IV)
Number of subjects: 670
Study 16037143 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 670
Study 12421239 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (100 mg once a day) with Erythromycin (200 mg three times a day)
Number of subjects: 23
Study 12421239 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (200 mg three times a day)
Number of subjects: 23
Study 10696321 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.3% ciprofloxacin
Number of subjects: 32
Study 10696321 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.3% ofloxacin
Number of subjects: 32
Study 8698859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol infusion during euglycemia (day 1)
Number of subjects: 16
Study 8698859 — intervention group
Group type: COMPARATOR
Intervention: Antecedent hypoglycemia (day 1)
Number of subjects: 16
Study 1679299 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% metipranolol
Number of subjects: 24
Study 1679299 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% metipranolol
Number of subjects: 24
Study 1679299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1679299 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% or 0.3% metipranolol
Number of subjects: 24